Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00114218
Other study ID # GOG-0130E
Secondary ID NCI-2012-02680CD
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2005

Study information

Verified date December 2014
Source Gynecologic Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent or persistent uterine cancer. Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.


Description:

OBJECTIVES:

I. Determine the antitumor activity of gemcitabine and docetaxel in patients with recurrent or persistent uterine carcinosarcoma.

II. Determine the nature and degree of toxicity of this regimen in these patients.

OUTLINE: This is a non-randomized, multicenter study. Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 1-4 years.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Histologically confirmed uterine carcinosarcoma

- Malignant mixed Müllerian tumor, homologous or heterologous type

- Recurrent or persistent disease

- Progressive disease after prior local therapy

- Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques OR = 10 mm by spiral CT scan

- At least 1 target lesion

- Tumors within a previously irradiated field are not considered target lesions except documented progression or biopsy to confirm persistence at least 90 days after completion of radiation therapy

- Received 1, and only 1, prior chemotherapy regimen for carcinosarcoma

- Initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment

- Ineligible for higher priority GOG protocol (i.e., any active phase III GOG protocol for the same patient population)

- Performance status - GOG 0-2

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Bilirubin = 1.5 times upper limit normal (ULN)

- SGOT = 2.5 times ULN

- Alkaline phosphatase = 2.5 times ULN

- Creatinine = 1.5 times ULN

- No severe pulmonary disease requiring oxygen supplementation

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No active infection requiring antibiotics

- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

- No neuropathy (sensory or motor) > grade 1

- At least 3 weeks since prior biologic therapy or immunotherapy for the malignancy

- No more than 1 prior non-cytotoxic (biologic or cytostatic) regimen (e.g., monoclonal antibodies, cytokines, or small molecule inhibitors of signal transduction) for recurrent or persistent disease

- Recovered from prior chemotherapy

- No more than 1 prior cytotoxic chemotherapy regimen, either as a single agent or combination therapy

- No prior docetaxel or gemcitabine

- At least 1 week since prior hormonal therapy for the malignancy

- Concurrent hormone replacement therapy allowed

- Recovered from prior radiotherapy

- Recovered from prior surgery

- At least 3 weeks since other prior therapy for the malignancy

- No prior cancer treatment that would preclude study therapy

Study Design


Intervention

Drug:
Gemcitabine Hydrochloride
Given IV
Docetaxel
Given IV

Locations

Country Name City State
United States Gynecologic Oncology Group Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Gynecologic Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate. CT scan or MRI if used to follow lesions for measurable disease every other cycle for the first 6 months; every 6 months thereafter until disease progression for up to 5 years.
Primary Incidence of Adverse Effects That Are Grade 3 or Greater as Assessed by Common Terminology Criteria for Adverse Events Version 3.0 Count of participants with Toxicities maximum grade greater than or equal to grade 3 Assessed every 28 days (28 days=1 cycle) while on study treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up
See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Completed NCT01168232 - Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Completed NCT00390234 - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Phase 2
Completed NCT00245102 - Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Phase 2
Completed NCT00025506 - Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Phase 2
Recruiting NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Phase 1/Phase 2
Recruiting NCT05619913 - EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Phase 2
Completed NCT00687687 - Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Phase 2
Terminated NCT01367301 - Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer N/A
Withdrawn NCT03902379 - Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer N/A
Completed NCT03694262 - The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Phase 2
Completed NCT01247571 - Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Terminated NCT01061606 - Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Phase 2
Completed NCT00075400 - Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Completed NCT00659360 - AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Completed NCT00238121 - Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Phase 2
Recruiting NCT05147558 - A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma Phase 2
Active, not recruiting NCT00954174 - Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Phase 3
Completed NCT00478426 - Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Phase 2
Active, not recruiting NCT05229601 - A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Phase 1